QTREX Quantum Ltd. Warrant
QTEXW
NASDAQ Global Market0.01
USD
-0.01
- -
QTREX Quantum Ltd. Warrant
QTEXW
(NASDAQ Global Market)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Inspira Technologies Oxy B.H.N. Ltd. engages in the development and commercialization of respiratory support solutions for adult and pediatric patients, focusing on innovative oxygenation and gas exchange technologies intended for hospital and acute care settings. The company operates primarily through its INSPIRA ART line of devices, including the ART100 system for minimally invasive, pump-free oxygenation and gas exchange, and related consumables and support services; it pursues ongoing development of HYLA blood sensors and complementary clinical technologies to expand its respiratory care platform. Headquartered in Israel with corporate operations and initial listing activities in the United States, Inspira maintains an international footprint aimed at global deployment and regulatory approvals where applicable. The company was founded to advance energy-efficient, low-impact respiratory support therapies that reduce complications associated with traditional mechanical ventilation, and it advances this objective through a combination of product development, clinical collaboration, and strategic partnerships. Main products and services -INSPIRA ART100 system: noninvasive, catheter-based oxygenation and gas exchange platform designed for hospital use; associated disposables, maintenance services, and clinical support -HYLA blood sensor technology: clinical-grade monitoring adjunct intended to inform respiratory therapy decisions -Clinical development programs and regulatory strategy support: including trial design, data collection, and submission activities -Post-market deployment services: clinician training, installation and commissioning, service and maintenance -Strategic partnerships and collaborations: research collaborations with healthcare providers and potential OEM partnerships for device integration -Commercial infrastructure and patient pathways support: logistics, distribution, and customer support services to facilitate adoption in hospital networks Latest major company changes -Strategic deployment expansion: progression toward broader U.S. hospital deployments of the ART100 system, including anticipated commercial activation and scaling milestones in 2025–2026 -Clinical and regulatory advancement: continued development and clinical evaluation of HYLA blood sensor technology to extend the company’s respiratory care platform -Partnership and financing activity: ongoing engagement in strategic partnerships and potential financing or warrant-related transactions associated with capital markets activities -Operational expansion: enhancements to domestic and international infrastructure to support post-market surveillance, customer service, and deployment of ART100 and related components -Corporate and branding evolution: reaffirmation of a focused, integrated respiratory care platform strategy as the company advances its commercialization plan Additional context -Industry and segments: medical devices, respiratory care, acute care hospital equipment -Target markets: hospitals, clinically managed care facilities, and regional health systems needing advanced respiratory support solutions -Geographic operations: activities and regulatory plans in the United States and international markets; headquarters located in Israel with global operations -Founding and corporate structure: founded to develop innovative respiratory support technologies; parent company publicly engaged in capital market activities related to its warrants and equity transactions -Subsidiaries/relations: corporate entities and affiliate structures linked to Inspira Technologies Oxy B.H.N. Ltd. and related holding/operating arrangements supporting device development and commercialization